Lim Rachel Wenrui, Keh Yann Shan, Yeo Khung Keong, Khanna Narendra Nath
National Heart Centre Singapore, Singapore.
Duke-NUS Medical School, Singapore.
AsiaIntervention. 2018 Sep 20;4(2):117-125. doi: 10.4244/AIJ-D-16-00013. eCollection 2018 Sep.
Takayasu's arteritis (TA) is a chronic non-specific vasculitis with variable presentation in different ethnicities and countries. Treatment options vary and are dependent on the stage and presentation of the disease. We aimed to review current literature related to TA, focusing on the role of endovascular treatment in revascularisation. The temporal course of the disease and stage at presentation influence the management of TA. Treatment options include medical therapy, endovascular intervention or surgical vascular reconstruction. The decision to intervene is individualised according to vascular anatomy and the presence of haemodynamically significant lesions. There are currently no clear guidelines regarding the choice between the endovascular and open surgical approaches, but studies have shown that endovascular procedures are associated with slightly higher rates of restenosis while surgical procedures have higher rates of thrombosis. Periprocedural immunosuppression is suggested if the disease is active at the point of intervention. This improves outcomes but at the cost of immunosuppression-related side effects. Careful long-term follow-up is essential due to the risk of disease activation or flare-up, requiring appropriate evaluation of the diseased vessels.
高安动脉炎(TA)是一种慢性非特异性血管炎,在不同种族和国家有不同表现。治疗方案各异,取决于疾病的阶段和表现。我们旨在回顾与TA相关的当前文献,重点关注血管内治疗在血管重建中的作用。疾病的时间进程和就诊时的阶段会影响TA的治疗。治疗选择包括药物治疗、血管内介入或外科血管重建。干预决策根据血管解剖结构和血流动力学显著病变的存在情况个体化。目前关于血管内和开放手术方法之间的选择尚无明确指南,但研究表明,血管内手术的再狭窄率略高,而手术的血栓形成率较高。如果疾病在干预时处于活动期,建议围手术期进行免疫抑制。这可改善预后,但会带来免疫抑制相关的副作用。由于存在疾病激活或复发的风险,需要对病变血管进行适当评估,因此仔细的长期随访至关重要。